Phase IIa Study Evaluating AZD7798 in Crohn’s Disease - AMALTHEA

Study identifier:D9690C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:2023-510487-12-00

Will Be Recruiting

Official Title

A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients with Moderate to Severe Crohn’s Disease

Medical condition

Moderate to severe Crohn’s disease

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD7798

Sex

All

Estimated Enrollment

192

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 17 Jun 2024
Estimated Primary Completion Date: 06 Apr 2026
Estimated Study Completion Date: 21 May 2027

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria